Veterinary

Veterinary

 

 

 

Pimobendan,74150-27-9
Pimobendan
Pimobendan,74150-27-9
CAS
74150-27-9
Molecular Formula
C19H18N4O2
Molecular Weight
334.377
Application
Used in the management of heart failure in dogs, most commonly caused by myxomatous mitral valve disease
Assay
99%
Certificate of analysis
Pimobendan,74150-27-9
View via PDF file
Pimobendan,74150-27-9
Specification
Appearance
White or slightly yellowish powder
Complies
Identification
The infrared absorption spectrum of the sample corresponds to that of the standard sample
Complies
Melting point
240℃
248 to 251℃
Water
<1.0%
0.41%
Specific rotation
+58 to +68°
+63°
Sulphated ash
<0.1%
0.07%
Related substances
Impurities A <0.1%
Complies
Impurities B <0.1%
Complies
Any other impurities <0.1%
Complies
Residual solvent
Methanol<3000ppm
30ppm
Ethyl acetate<0.01%
Complies
Assay
>99.80%
99.82%
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Packing
Pimobendan,74150-27-9
Packing 1
1g
Packing 2
10g
Packing 3
100g
Packing 4
1000g
Packing 5
5000g
Bulk request
sales@lanospharma.com
 
Related Veterinery compounds
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(Pimobendan,74150-27-9).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.